Frequency Therapeutics FREQ made its public debut Thursday morning, opening at $11.20 after being priced at $14 per share.
The company shares are trading on the Nasdaq under the ticker “FREQ.”
Frequency Therapeutics is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
JPMorgan, Goldman Sachs and Cowen are acting as joint book running managers for the offering.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
